The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, ...

One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

Caris Life Sciences' shares jumped nearly 29% in their Nasdaq debut on Wednesday, fetching the cancer diagnostic firm a ...

Caris Life Sciences shares rose on their first day of trading in their debut on Nasdaq. The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was ...

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris ...

Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company ...